Leo Pharma cleaves R&D organization, hires veteran dermatologist to lead early development
An R&D reshuffle at Leo Pharma also means Thorsten Thormann, current VP for research and early development, will leave the medical dermatology company.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
A substantial change in how Leo Pharma approaches drug development is now being followed by a new leadership structure, the Danish medical dermatology company announced in a press release on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Yearlong losses have almost emptied out Leo Pharma's coffers
For subscribers
Leo Pharma books multimillion-dollar loss in 2022
For subscribers
.jpg&w=384&q=75)
